These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36629737)

  • 21. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.
    Gaine S; Simonneau G
    Eur Respir Rev; 2013 Dec; 22(130):487-94. PubMed ID: 24293464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guanylate cyclase stimulators for pulmonary hypertension.
    Wardle AJ; Seager MJ; Wardle R; Tulloh RM; Gibbs JS
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011205. PubMed ID: 27482837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 24. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional Variation in Pulmonary Arterial Hypertension in the United States: The Pulmonary Hypertension Association Registry.
    Fling C; De Marco T; Kime NA; Lammi MR; Oppegard LJ; Ryan JJ; Ventetuolo CE; White RJ; Zamanian RT; Leary PJ
    Ann Am Thorac Soc; 2023 Dec; 20(12):1718-1725. PubMed ID: 37683277
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.
    Kearney K; Brown K; Celermajer DS; Collins N; Cordina R; Corrigan C; Dwyer N; Feenstra J; Keating D; Keogh A; Kotlyar E; Lavender M; McWilliams T; Williams T; Whitford H; Weintraub R; Wrobel J; Ellender C; Anderson J; Lau EM;
    Chest; 2024 Apr; 165(4):967-977. PubMed ID: 37951349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis.
    Degano B; Sitbon O; Savale L; Garcia G; O'Callaghan DS; Jaïs X; Humbert M; Simonneau G
    Chest; 2010 Jun; 137(6):1297-303. PubMed ID: 20118205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension.
    Alabed S; Garg P; Alandejani F; Dwivedi K; Maiter A; Karunasaagarar K; Rajaram S; Hill C; Thomas S; Gossling R; Sharkey MJ; Salehi M; Wild JM; Watson L; Hameed A; Charalampopoulos A; Lu H; Rothman AMK; Thompson AAR; Elliot CA; Hamilton N; Johns CS; Armstrong I; Condliffe R; van der Geest RJ; Swift AJ; Kiely DG
    Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37414419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with the 6-minute walk distance in patients with systemic sclerosis.
    Sanges S; Giovannelli J; Sobanski V; Morell-Dubois S; Maillard H; Lambert M; Podevin C; Lamblin N; De Groote P; Bervar JF; Perez T; Matran R; Rémy-Jardin M; Hatron PY; Hachulla É; Launay D
    Arthritis Res Ther; 2017 Dec; 19(1):279. PubMed ID: 29246248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization.
    Polkey MI; Spruit MA; Edwards LD; Watkins ML; Pinto-Plata V; Vestbo J; Calverley PM; Tal-Singer R; Agustí A; Bakke PS; Coxson HO; Lomas DA; MacNee W; Rennard S; Silverman EK; Miller BE; Crim C; Yates J; Wouters EF; Celli B;
    Am J Respir Crit Care Med; 2013 Feb; 187(4):382-6. PubMed ID: 23262518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determining the Minimal Clinically Important Difference for 6-Minute Walk Distance in Fibromyalgia.
    Kaleth AS; Slaven JE; Ang DC
    Am J Phys Med Rehabil; 2016 Oct; 95(10):738-45. PubMed ID: 27003201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity.
    Neal JE; Lee AS; Burger CD
    Clin Respir J; 2014 Oct; 8(4):404-9. PubMed ID: 24308300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.
    Kolaitis NA; Zamanian RT; de Jesus Perez VA; Badesch DB; Benza RL; Burger CD; Chakinala MM; Elwing JM; Feldman J; Lammi MR; Mathai SC; McConnell JW; Presberg KW; Robinson JC; Sager J; Shlobin OA; Simon MA; Kawut SM; Glidden DV; Singer JP; De Marco T;
    Ann Am Thorac Soc; 2021 Apr; 18(4):613-622. PubMed ID: 33064950
    [No Abstract]   [Full Text] [Related]  

  • 35. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
    Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E
    Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
    Porhownik NR; Myers R; Bshouty Z
    Can Respir J; 2013; 20(2):111-5. PubMed ID: 23616968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.
    Gupta R; Baughman RP; Nathan SD; Wells AU; Kouranos V; Alhamad EH; Culver DA; Barney J; Carmona EM; Cordova FC; Huitema M; Scholand MB; Wijsenbeek M; Ganesh S; Birring SS; Price LC; Wort SJ; Shlobin OA
    Respir Med; 2022 May; 196():106801. PubMed ID: 35316723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex differences in response to tadalafil in pulmonary arterial hypertension.
    Mathai SC; Hassoun PM; Puhan MA; Zhou Y; Wise RA
    Chest; 2015 Jan; 147(1):188-197. PubMed ID: 25122150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of Iron Deficiency on Clinical and Haemodynamic Parameters in Pulmonary Arterial Hypertension Cohorts.
    Saluja P; Gautam N; Amisha F; Salah HM; Smith J; Biyani S; Venkata AN; Al'Aref SJ; Jagana R
    Heart Lung Circ; 2022 Dec; 31(12):1594-1603. PubMed ID: 36402703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physical Activity and Its Association with Traditional Outcome Measures in Pulmonary Arterial Hypertension.
    Minhas J; Shou H; Hershman S; Zamanian R; Ventetuolo CE; Bull TM; Hemnes A; Chakinala MM; Mathai S; Al-Naamani N; Ellenberg S; Matura LA; Kawut SM; Shcherbina A
    Ann Am Thorac Soc; 2022 Apr; 19(4):572-582. PubMed ID: 34473938
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.